Objective: The purpose of this investigation is to evaluate the efficacy of the occupational slip, trip and fall (STF) risk assessment test developed by the Japan Industrial Safety and Health Association (JISHA). We further intended to simplify the test to improve efficiency.
Methods: A previous cohort study was performed using 540 employees aged ≥50 years who took the JISHA's STF risk assessment test. We conducted multivariate analysis using these previous results as baseline values and answers to questionnaire items or score on physical fitness tests as variables. The screening efficiency of each model was evaluated based on the obtained receiver operating characteristic (ROC) curve.
Results: The area under the ROC obtained in multivariate analysis was 0.79 when using all items. Six of the 25 questionnaire items were selected for stepwise analysis, giving an area under the ROC curve of 0.77.
Conclusion: Based on the results of follow-up performed one year after the initial examination, we successfully determined the usefulness of the STF risk assessment test. Administering a questionnaire alone is sufficient for screening subjects at risk of STF during the subsequent one-year period.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963548 | PMC |
| http://dx.doi.org/10.2486/indhealth.2015-0125 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk factors associated with subtalar fusion within 5 years following calcaneal ORIF.
Foot (Edinb)
December 2024
Maimonides Medical Center, Department of Orthopedic Surgery, 4802 Tenth Avenue, Brooklyn, NY 11219, United States.
Background: Although most calcaneal fractures are managed with open reduction internal fixation (ORIF), they can ultimately lead to subtalar arthritis and pain requiring subtalar fusion when conservative treatments prove ineffective. Understanding the risk factors associated with subtalar fusion (STF) after calcaneal ORIF is crucial for optimizing patient outcomes and treatment strategies. This study aimed to comprehensively evaluate these risk factors and their association with the incidence of STF, including patient demographics, medical comorbidities, same day and 90-day reimbursement data.
View Article and Find Full Text PDFPerformance of a Short Version of the Everyday Cognition Scale (ECog-12) to Detect Cognitive Impairment.
J Prev Alzheimers Dis
November 2024
Rachel L. Nosheny, Ph.D., Assistant Professor, University of California, San Francisco, Department of Psychiatry, San Francisco VA Medical Center, 4150 Clement Street (114M), San Francisco, CA 94121, Tel: 650-468-0619, Fax: 415-668-2864, email:
Background: The Everyday Cognition (ECog) 12-item scale, a functional decline measurement, can distinguish dementia from cognitively unimpaired (CU). Limited data compare ECog-12 performance by raters (self vs. informant) and scoring systems (average numeric vs.
View Article and Find Full Text PDFCo-expression of multiple transcription factors is associated with clinical features and endocrine prognosis in growth hormone-secreting pituitary adenomas.
Endocrine
October 2024
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, PR China.
Background: The types of growth hormone-secreting pituitary adenomas are diverse, we have found that there are significant differences in clinical features and prognosis between PIT-1 single-cell spectrum growth hormone adenomas and growth hormone phenotypic polyhormonal adenomas.
Methods: This study examined a cohort of 193 patients with growth hormone-secreting pituitary adenoma (GHPA), stratifying them into two groups: PIT-1 single transcription factor positive growth hormone adenoma (STF-GHPA) and Multiple transcription factor-positive growth hormone-secreting adenomas (MTF-GHPA). The objective was to compare these two groups' clinical characteristics.
Article Synopsis
- The study aimed to assess the safety and pharmacokinetics of a new drug, BI 1291583, which inhibits cathepsin C to potentially reduce inflammation in bronchiectasis patients.
- Conducted as a randomized, double-blind, placebo-controlled trial, it involved healthy Japanese males and evaluated both single and multiple doses for any related adverse events and drug absorption levels.
- Results indicated that the drug was safe and well-tolerated, with no serious side effects and an adequate benefit-risk ratio, suggesting it can be used in future clinical trials involving bronchiectasis patients without needing dose adjustments.
Recurrent cardiovascular and limb events in 294,428 patients with coronary or peripheral artery disease or ischemic stroke on antiplatelet monotherapy: The RESRISK cohort study.
Atherosclerosis
November 2024
Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, United Kingdom.
Background And Aims: Utilising real-world data, we quantified the burden of cardiovascular risk factors and long-term residual risk of atherothrombotic events among routine care cohorts with coronary (CAD) or peripheral (PAD) artery disease or ischemic stroke (IS) on guideline-recommended antiplatelet monotherapy (APMT).
Methods: Retrospective cohort study using data (2010-2020) from the United Kingdom Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics, including adults with CAD, PAD or IS who were first prescribed APMT (CAD/IS: aspirin; PAD: clopidogrel). Primary outcomes (recurrent events): major adverse cardiovascular events (MACE) for CAD/PAD/IS cohorts, major adverse limb events (MALE) for PAD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!